HARVARD BIOSCIENCE INC HBIO Income Statement

Harvard bioscience inc (HBIO)

Income statement / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09
Revenues
116,176	120,774	-	-	-	-	-	-	-	-	-
Revenues
-	-	77,407	104,521	108,664	108,663	105,171	111,171	108,864	108,179	85,772
Cost of revenues
51,854	57,593	38,237	56,106	59,941	59,319	57,475	58,831	58,672	56,372	44,089
Gross profit
64,322	63,181	39,170	48,415	48,723	49,344	47,696	52,340	50,192	51,807	41,683
Sales and marketing expenses
23,264	24,443	15,082	20,486	20,577	18,225	17,330	18,287	16,909	16,384	11,763
General and administrative expenses
22,760	21,382	17,525	20,950	19,832	16,826	17,887	18,121	17,630	17,674	15,109
Research and development expenses
10,715	10,988	5,645	5,392	6,420	4,880	4,154	4,344	3,874	4,669	4,396
Restructuring charges (credits)
-	-	-	-4	788	1,027	2,150	310	467	498	516
Amortization of intangible assets
5,746	5,384	1,553	2,722	2,819	2,578	2,590	2,752	2,746	2,364	1,844
Gain on sale of assets, net
-	-	-	-	-	810	0	0	-	-	-
Impairment charges
1,460	-	-	676	0	0	-	-	-	-	-
HART transaction costs
-	-	-	-	-	-	2,048	696	161	-	-
Loss on sale of AHN
-	-	-	1,190	0	0	-	-	-	-	-
Total operating expenses
63,945	62,197	39,805	51,412	50,436	42,726	46,159	44,510	41,787	41,589	33,628
Operating loss
377	984	-635	-2,997	-1,713	6,618	1,537	7,830	8,405	10,218	8,055
Other expense:
Interest expense, net
-5,410	-5,367	-	-	-	-	-	-	-	-	-
Changes in fair value of acquisition contingencies
-	-	-	-	-	-	-	-	-	429	2,600
Foreign exchange
-	-	-534	737	210	-150	-139	-113	-41	-89	-302
Interest expense, net
-	-	713	639	846	990	955	584	752	677	277
Interest income
-	-	0	0	0	74	43	46	65	65	29
Other (income) expense, net
-469	-3,592	-739	-179	-1,259	-1,135	-51	-287	-809	-383	-293
Total other expense
-5,879	-8,959	-1,986	-81	-1,895	-2,201	-1,102	-938	-1,537	-655	1,757
Loss before income taxes
-5,502	-7,975	-2,621	-3,078	-3,608	4,417	435	6,892	6,868	9,563	9,812
Income tax expense
-815	-3,676	-605	1,229	15,431	2,062	-288	2,398	1,579	-9,452	2,673
Loss from continuing operations
-4,687	-4,299	-2,016	-	-	-	-	4,494	5,289	19,015	7,139
Discontinued operations:
Income from discontinued operations before income taxes
-	936	534	-	-	-	-	-	-	-	-
Income tax benefit from discontinued operations
0	-441	-617	-	-	-	-	-	-	-	-
Income from discontinued operations
-	1,377	1,151	-	-	-	-	-	-	-	-
Income from discontinued operations, net of tax
-	-	-	-	-	-	-	-	-	0	94
Loss from Discontinued Operations, Net of Tax, Attributable to Parent
-	-	-	-	-	-	-	-2,124	-1,477	0	94
Net loss
-4,687	-2,922	-865	-4,307	-19,039	2,355	-1,830	2,370	3,812	19,015	7,233
Loss per share:
Basic loss per common share from continuing operations (in dollars per share)
-0.12	-0.12	-0.06	-	-	-	0.02	0.16	0.19	0.66	0.24
Basic earnings per common share from discontinued operations (in dollars per share)
-	0.04	0.03	-	-	-	-0.08	-0.07	-0.05	0.00	0.00
Basic loss per common share (in dollars per share)
-0.12	-0.08	-0.02	-0.13	-0.57	0.07	-0.06	0.09	0.14	0.66	0.24
Diluted loss per common share from continuing operations (in dollars per share)
-0.12	-0.12	-0.06	-	-	-	0.02	0.15	0.18	0.65	0.24
Diluted earnings per common share from discontinued operations (in dollars per share)
-	0.04	0.03	-	-	-	-0.08	-0.07	-0.05	0.00	0.00
Diluted loss per common share (in dollars per share)
-0.12	-0.08	-0.02	-0.13	-0.57	0.07	-0.06	0.08	0.13	0.65	0.24
Weighted-average common shares:
Basic (in shares)
37,813	36,453	34,753	34,211	33,592	32,170	30,384	28,799	28,451	28,967	29,649
Diluted (in shares)
37,813	36,453	34,753	34,211	33,592	33,236	31,913	29,792	29,818	29,404	29,946
Net Loss
-4,687	-2,922	-865	-4,307	-19,039	-	-1,830	2,370	3,812	19,015	7,233
Other comprehensive (loss):
Foreign currency translation adjustments
-	-	-	-	-	-	-	-	-	-2,057	-
Derivatives qualifying as hedges, net of tax:
Comprehensive loss
-	-	-	-	-	-	-	-	-	16,953	-